Mubadala Participates in Investment in Science 37
Posted on 08/23/2020
Los Angeles-based Science 37, Inc. is a clinical trials platform. Science 37 raised US$ 37 million in funding that was led by Lux Capital, Redmile Group, and PPD, Inc.. Other investors in the round include Mubadala Ventures (part of Mubadala Investment Company), Novartis AG, Amgen, Sanofi Ventures, GV (part of Alphabet), Glynn Capital, and LifeSci Ventures. Notable new investors include LifeSci Ventures and Mubadala Ventures.
Science 37 will use the new capital to support its growth and expand its technology platform. Science 37 is led by David Coman, a former executive at ERT and Quintiles International.
